Biocon Limited is a leading global biopharmaceutical company focused on developing affordable biologics, biosimilars, generic formulations, and research services. Founded in 1978 by Kiran Mazumdar-Shaw, Biocon has evolved into one of India’s foremost biotechnology companies with operations spanning more than 120 countries. The company specializes in insulin, monoclonal antibodies, oncology, immunology, and other biologic therapies addressing chronic and life-threatening diseases. Through its subsidiaries, including Biocon Biologics, the company has expanded its global biosimilar portfolio, strengthening its presence in regulated markets such as the United States and Europe. Biocon invests significantly in research, innovation, and advanced manufacturing technologies to deliver high-quality, cost-effective therapies. Its integrated business model combines drug development, commercialization, and contract research, enabling the company to serve patients, healthcare providers, and pharmaceutical partners worldwide. Biocon continues to play a pivotal role in improving global healthcare accessibility through innovation and scientific excellence.
NSE: BIOCON | BSE: 532523
Bengaluru, Karnataka, India
